Consensus Zentalis Pharmaceuticals, Inc.

Equities

ZNTL

US98943L1070

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-21 pm EDT			5-day change	1st Jan Change
11.58 ^USD	-1.78%		-0.77%	-23.56%

May. 08	Stifel Adjusts Price Target on Zentalis Pharmaceuticals to $32 From $36, Maintains Buy Rating	MT
May. 07	Zentalis Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Evolution of the average Target Price on Zentalis Pharmaceuticals, Inc.

Price target over the last 5 years

History of analyst recommendation changes

0ad34b4a7f6b0f2986acdc88a9182d92.v14LO0D-XfV7OqKqF85LgHCd4VjmoC8dOKHLo1syd4s.3BxxegGYD74TSdPpfoYM9R3fkA-C1GZLQf6h0Qh3B--SFzJwdLwNkhZ3xQ~5c9b9e3a8f61a57bfd5d3fd41c0f4bd9

Analyst Recommendations on Zentalis Pharmaceuticals, Inc.

Stifel Adjusts Price Target on Zentalis Pharmaceuticals to $32 From $36, Maintains Buy Rating	May. 08	MT
Wedbush Raises Zentalis Pharmaceuticals' PT to $15 From $12, Tweaks Financing Assumptions, Says Still on Track to Share Multiple Azenosertib Datasets in 2024, 2025; Keeps Neutral Rating	Feb. 28	MT
Wedbush Raises Immunome's PT to $19 From $12 After Acquiring IM-1021 From Zentalis Pharmaceuticals, Maintains Outperform Rating	Jan. 23	MT
UBS Adjusts Zentalis Pharmaceuticals Price Target to $28 From $52, Maintains Buy Rating	Nov. 28	MT
Wedbush Downgrades Zentalis Pharmaceuticals to Neutral From Outperform After Announced Updates to Azenosertib Strategy in Platinumsensitive Ovarian Cancer; Cuts PT to $12 From $38	Nov. 08	MT
Stifel Cuts Price Target on Zentalis Pharmaceuticals to $36 From $44, Maintains Buy Rating	Nov. 07	MT
HC Wainwright Lowers Price Target on Zentalis Pharmaceuticals to $46 From $55, Maintains Buy Rating	Nov. 07	MT
Morgan Stanley Adjusts Price Target on Zentalis Pharmaceuticals to $38 From $55, Maintains Overweight Rating	Nov. 07	MT
Wells Fargo Adjusts Price Target on Zentalis Pharmaceuticals to $50 From $51, Maintains Overweight Rating	23-08-10	MT
Stifel Adjusts Price Target on Zentalis Pharmaceuticals to $50 From $45, Maintains Buy Rating	23-06-07	MT
Wedbush Raises Zentalis Pharmaceuticals' Price Target to $38 From $31, Says Topline Azeno Combo Data Impresses; Keeps Outperform Rating	23-05-26	MT
Jefferies Adjusts Price Target on Zentalis Pharmaceuticals to $70 From $120, Maintains Buy Rating	23-05-19	MT
Wedbush Trims Zentalis Pharmaceuticals' Price Target to $31 From $33, Adjusts Launch Timing Assumptions; Keeps Outperform Rating	23-05-11	MT
Wedbush Lifts Zentalis Pharmaceuticals' PT to $33 From $32, Sees Number of Compelling Value Opportunities Ahead; Keeps Outperform Rating	23-03-02	MT
UBS Adjusts Zentalis Pharmaceuticals Price Target to $52 From $91, Maintains Buy Rating	22-11-21	MT
UBS Adjusts Zentalis Pharmaceuticals Price Target to $52 From $91, Maintains Buy Rating	22-11-18	MT
Wedbush Lowers Price Target on Zentalis Pharmaceuticals to $32 From $51, Keeps Outperform Rating	22-11-14	MT
SVB Securities Trims Price Target on Zentalis Pharmaceuticals to $27 From $42, Affirms Outperform Rating	22-11-11	MT
Morgan Stanley Cuts Price Target on Zentalis Pharmaceuticals to $55 From $60, Keeps Overweight Rating	22-11-11	MT
Guggenheim Lowers Price Target on Zentalis Pharmaceuticals to $28 From $55, Maintains Buy Rating	22-11-11	MT
Oppenheimer Adjusts Zentalis Pharmaceuticals Price Target to $50 From $80, Maintains Outperform Rating	22-11-10	MT
SVB Securities Cuts Price Target on Zentalis Pharmaceuticals to $27 From $42, Maintains Outperform Rating	22-11-10	MT
ANALYST RECOMMENDATIONS : Walt Disney, Salesforce, ServiceNow, Cigna, Equinix...	22-08-12
Morgan Stanley Lowers Zentalis Pharmaceuticals' Price Target to $60 From $95, Keeps Overweight Rating	22-08-11	MT
SVB Securities Lowers Zentalis Pharmaceuticals Price Target to $42 From $67, Maintains Outperform Rating	22-08-10	MT